| 安罗替尼治疗肺癌的临床研究进展 |
| |
| 引用本文： | 刘艺婧,卢凯华. 安罗替尼治疗肺癌的临床研究进展[J]. 现代肿瘤医学, 2021, 0(16): 2936-2939. DOI: 10.3969/j.issn.1672-4992.2021.16.038 |
| |
| 作者姓名： | 刘艺婧 卢凯华 |
| |
| 作者单位： | 南京医科大学第一附属医院（江苏省人民医院）肿瘤科,江苏 南京 210029 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81672949）;国家自然科学基金（编号:81672949） |
| |
| 摘 要： | 肺癌现已成为我国每年发病及死亡病例数最多的恶性肿瘤.本综述介绍了安罗替尼的作用机制,回顾了单药使用及联合用药的临床实验结果,并结合真实世界回顾性研究分析安罗替尼的疗效及使用的安全性.安罗替尼不论单药还是联合方案均有显著疗效,但受限于现有研究设计的小样本量及病例纳入标准患者的基线PS与临床现实的不完全相符,其结果存在偏差...
|
| 关 键 词： | 安罗替尼 肺癌 单药疗效 联合治疗 进展 |
Research progress of anlotinib in the treatment of lung cancer |
| |
| LIU Yijing,LU Kaihua. Research progress of anlotinib in the treatment of lung cancer[J]. Journal of Modern Oncology, 2021, 0(16): 2936-2939. DOI: 10.3969/j.issn.1672-4992.2021.16.038 |
| |
| Authors: | LIU Yijing LU Kaihua |
| |
| Affiliation: | Department of Medical Oncology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Jiangsu Nanjing 210029,China. |
| |
| Abstract: | Lung cancer has become the most common malignant tumor in China.This artical introduces the mechanism of anlotinib,which is known as a new vascular targeting drug,and reviews the clinical experimental results of single and combined use of anlotinib.We also analyse the efficacy and safety of anlotinib used in real world.It is pointed out that both single drug and combination regimen of anlotinib have significant curative effect,but limited by the small sample size of existing research design and the fact that the baseline PS of patients in the case inclusion standard is not completely consistent with the clinical reality and the results are biased.It is suggested that we can focus on the combination regimen of anlotinib to provide patients with more ideal choice of treatment mode in the future. |
| |
| Keywords: | anlotinib lung cancer single drug combination therapy progress |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
